Literature DB >> 12796832

The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.

Paul W Wirtz1, Marianne G Nijnuis, Mohammad Sotodeh, Luc N A Willems, Joey J Brahim, Hein Putter, Axel R Wintzen, Jan J Verschuuren.   

Abstract

We studied the epidemiology of myasthenia gravis (MG) and the Lambert-Eaton myasthenic syndrome (LEMS), and their association with small cell lung carcinoma (SCLC) and thymoma, in a well defined region of the Netherlands. Available data on all the patients with MG, LEMS, thymoma or SCLC living between 1 January 1990 and 31 December 1999 in the northern region of South Holland, with a population of 1.7 million inhabitants, were evaluated. A total of 202 patients with MG (20 with thymoma) and ten patients with LEMS (seven with SCLC) were identified. LEMS was 46 times less prevalent (2.32 x 10(-6)) than MG (106.1 x 10(-6)), whereas the annual incidence rate of LEMS was 14 times lower (0.48 x 10(-6)) than of MG (6.48 x 10(-6)), reflecting the poor survival of LEMS patients with SCLC. SCLC was diagnosed in 1593 patients, seven (0.44 %) of whom developed LEMS. Mean age at diagnosis of SCLC was significantly lower in SCLC patients with LEMS (p = 0.006). A thymoma was diagnosed in 32 patients, of whom the ten patients with MG (31 %) had a younger age at diagnosis of thymoma than the patients without MG (p = 0.27). This study confirms the increasing prevalence of MG over the last few decades as reported by others, and underscores the relative rarity of LEMS. The frequency of LEMS in our patients with SCLC was lower than reported in previous studies. In patients with a SCLC or thymoma, the tumour was diagnosed at younger age in those who had the associated myasthenic syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796832     DOI: 10.1007/s00415-003-1063-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

Review 1.  Voltage gated calcium channel antibody-related neurological diseases.

Authors:  Can Ebru Bekircan-Kurt; Eda Derle Çiftçi; Aslı Tuncer Kurne; Banu Anlar
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.

Authors:  Erik H Niks; Jan B M Kuks; Jan J G M Verschuuren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

Review 3.  Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

Authors:  A Evoli; R Liguori; A Romani; R Mantegazza; A Di Muzio; B Giometto; E Pegoraro; C Rodolico; M C Vigliani
Journal:  Neurol Sci       Date:  2014-01-31       Impact factor: 3.307

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

5.  Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families.

Authors:  Paul W Wirtz; Jennifer Bradshaw; Axel R Wintzen; Jan J Verschuuren
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

Review 6.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

Review 7.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

Review 8.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

9.  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.

Authors:  Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

Review 10.  Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.

Authors:  Tyler B Tarr; Peter Wipf; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.